Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma

Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to Temozolomide (TMZ) and the ability of [(18)F]FLT...

Descripción completa

Detalles Bibliográficos
Autores principales: Valtorta, Silvia, Lo Dico, Alessia, Raccagni, Isabella, Martelli, Cristina, Pieri, Valentina, Rainone, Paolo, Todde, Sergio, Zinnhardt, Bastian, De Bernardi, Elisabetta, Coliva, Angela, Politi, Letterio S., Viel, Thomas, Jacobs, Andreas H., Galli, Rossella, Ottobrini, Luisa, Vaira, Valentina, Moresco, Rosa Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126706/
https://www.ncbi.nlm.nih.gov/pubmed/34012924
http://dx.doi.org/10.3389/fonc.2021.664149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126706/
https://www.ncbi.nlm.nih.gov/pubmed/34012924
http://dx.doi.org/10.3389/fonc.2021.664149

Ejemplares similares